Metagenomi Therapeutics, Inc. (MGX) Operating cash flow 2023–2025
Metagenomi Therapeutics, Inc. (MGX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$88.9MFY2025 · since FY2023: -$91.4M → -$88.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$88.9M | +18.5% |
| FY2024 | -$109.1M | -19.3% |
| FY2023 | -$91.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice